# AFP in hepatocellular carcinoma

1 EU-approved indication in hepatocellular carcinoma needs a AFP result: ramucirumab (2nd line, advanced).

## Approved indications

### AFP

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Ramucirumab](https://oncolabels.com/drugs/ramucirumab) (Cyramza) | Serum AFP ≥ 400 ng/ml | Monotherapy | 2nd line, advanced | After sorafenib |

## Label wording

- **Ramucirumab** (Cyramza), Hepatocellular carcinoma, 2nd line, advanced: “Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/hepatocellular-carcinoma/afp